Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib Continued Access
NCT04949425Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoint: Number of patients with serious and non-serious adverse events. Started Sep 2021; status: terminated.
02
Drugs
adavosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04949425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04949425.